‘This Is Crazy’: Health Experts Call for Changes to the No Surprises Act

Why It Matters

Inflated IDR awards drive up insurance premiums and strain provider‑payer negotiations, threatening the affordability goals of the No Surprises Act.

Key Takeaways

• IDR disputes surged to 3.4 million, far exceeding forecasts.
• Providers file 99% of disputes and win at 4.5× rate.
• IDR process cost $5 billion from 2022‑2024.
• Awards sometimes inflate to tens of millions, e.g., $255 million.
• Industry urges regulatory and congressional reforms to curb abuse.

Pulse Analysis

The No Surprises Act was hailed as a consumer‑protection milestone, eliminating surprise balance‑billing by mandating a 30‑day negotiation window and, if needed, an Independent Dispute Resolution (IDR) arbitration. While the framework succeeded in shielding patients, it also introduced a new battleground where insurers and providers settle payment disagreements. Over time, the arbitration mechanism has become a revenue lever for some providers, who strategically file disputes to secure outsized settlements.

Recent data reveal a dramatic mismatch between expectations and reality. CMS projected roughly 55,000 IDR cases through mid‑2025, yet actual filings topped 3.4 million, with providers initiating 99% of them and prevailing at a median rate 4.5 times higher than standard in‑network payments. The financial toll is stark: $5 billion in IDR‑related costs between 2022 and 2024, and isolated awards that dwarf the underlying claims—such as a $7,000 lab test yielding a $255 million judgment. These anomalies inflate premiums, force insurers to allocate extensive staffing resources, and erode confidence in the arbitration process.

Industry leaders, including coalition advocates and health‑insurance executives, argue that immediate regulatory tweaks are essential. Proposals range from tightening eligibility criteria for arbitration to redesigning incentive structures that discourage frivolous filings. Some suggest congressional action to overhaul the IDR framework entirely, ensuring transparent, data‑driven adjudication. As policymakers weigh these reforms, the balance between protecting patients and preventing provider‑driven cost escalation remains the central challenge.